The benefit and risk of whole brain radiation therapy (WBRT) compared to locally limited radiation therapy was assessed in 61 patients with solitary brain metastases from non-small cell lung cancer without an unresectable active primary lesion or systemic dissemination in the other organs. Twenty three patients received local irradiation (Group A), and 38 patients received whole brain irradiation with or without local irradiation (Group B). The survival was significantly better in Group A than in Group B (p < 0.05), with median survivals of 83.1 and 30.7 weeks, respectively. One-year local recur rence rates were 7% in Group A and 21% in Group B, but the difference was not statistically signifi cant. The 1-year distant recurrence rate was similar at 18%. Radiation-induced dementia occurred in two patients in Group A (8.7%) and seven in Group B (18.4%), but was not statistically signifi cant (p = 0.30). There is no obvious benefit and possible disadvantages of WBRT compared to local irradiation for the population of patients investigated in this study. Intraoperative radiation therapy or stereotactic radiosurgery without WBRT should be considered in the patients with solitary brain metastases.
Introduction
Recent prospective and retrospective studies on the treatment of solitary brain metastases have shown that surgical resection combined with radiation ther apy is superior to radiation therapy alone in both local control and survival. 11,16-11,11) The widely ac cepted consensus is to resect the solitary metastasis if accessible, followed by adjuvant radiation therapy. Stereotactic radiosurgery is an alternative to surgery which has been achieving excellent results, especially for patients with a surgically inaccessible lesion or in poor general condition. Whole brain radiation ther apy (WBRT) is commonly combined with these rela tively aggressive treatments of the original metastatic lesion. 11, 11, 24 The rationale for WBRT is that it should significantly reduce the risk of multiple in tracranial recurrences which could develop from microscopic metastases in the brain. Autopsy reports have showed that 60-80% of brain metastases are multiple,"') but these patients most likely died of progressive disease, and therefore may not be typical of clinical patients. Although several previous stud ies supported this treatment strategy,6°lo> the popula tions were not homogeneous in the factors which are most likely influence the risk of multiple intracranial relapse, such as the histological type of the tumor or the extent of systemic disease. The neurotoxicity of WBRT has recently been at tracting more attention.',',',',")
WBRT is known to in duce brain atrophy and dementia in a significant number of patients even if the doses are below the threshold for radiation necrosis."" For patients with an expected survival of longer than a year, the risk of radiation-induced dementia is much more significant and may negate the benefit of WBRT.') Therefore, the use of WBRT in patients with solitary brain metastasis should be evaluated in a reasonably homogeneous group of patients by comparing the fre quency of local recurrence (relapse of the same le sion) and distant recurrence (new metastatic site). A randomized study is ideal but difficult to per form, given that not even any reliable retrospective studies have been reported.
The present retrospective study compared the effec tiveness of WBRT and locally limited radiation ther apy in the treatment of solitary brain metastases from non-small cell lung cancer, the most frequent source of brain metastases, by evaluating survival, lo cal and distant recurrence rates, and frequency of radiation-induced dementia. WBRT was delivered using a 4 MV linear accelera tor beam through opposed lateral fields. Total doses of 30-50 Gy were administered in 2 Gy daily frac tions. Local external beam radiation therapy was also delivered by a 4 MV linear accelerator beam to the target volume consisting of the contrast-en hanced lesion on CT scan with a 2 cm margin. When local external beam radiation therapy was used without surgical resection, a total dose of 60 Gy was delivered in 2 Gy daily fractions. Intraoperative radi ation therapy used a 20 MeV betatron apparatus, and 15-25 Gy was delivered in a single dose with the energy of the electron beam selected to deliver 90% of the maximal dose to 1-2 cm from the floor of the tumor bed.") The wound was closed in layers after irradiation. Adjuvant chemotherapy with cis platin (30-50 mg/body/wk for 2-3 wks) was admin istered with the radiation therapy in about half of the patients (Table 1) .
Survival was calculated from the time treatment of the brain metastasis was initiated. Recurrence of the brain metastasis was classified as either local recur rence (recurrence in or around the primary site), or distant recurrence (new brain metastasis in distant region from the primary metastasis). Death was at tributed to either a systemic or a neurological cause if the cause could be determined. A systemic cause was defined as organ failure, fatal infection, or hemorrhage with stable or improving neurological condition.
Death was ascribed to a neurological cause when the patient died of a progressive neuro logical deficit due to an expanding mass or of acute neurological deterioration due to hemorrhage into the tumor. Survival curves were drawn using the Kaplan-Meier product-limit method, and compari sons were made using a generalized Wilcoxon test."' Radiation-induced dementia was diagnosed if a patient developed symptoms of dementia after radia tion therapy, such as memory disturbance, cognitive dysfunction, gait disturbance, with significant brain atrophy revealed by CT, but without progress of metastatic lesions. Results Table 1 shows there was no significant difference in sex, age, pattern of onset, histology, or size or loca tion of the metastasis between the patient groups. The median survival was 83.1 weeks for Group A and 30.7 weeks for Group B patients (Fig. 1) . The difference was statistically significant (p < 0.05). The median survival for patients who underwent surgical resection of the metastatic lesion was 61.7 weeks in 18 patients of Group A and 42.3 weeks in 30 pa tients of Group B. Although the data suggested a similar trend, the difference was not statistically sig nificant (p = 0.168). The cause of death was deter mined in 13 patients in Group A and 24 in Group B (Table 2) . Death was attributed to a neurological cause in four patients in Group A and six in Group B.
Patients in Group A tended to have fewer local recurrences than those in Group B, although there was no statistically significant difference. The 1-year local recurrence rate was 7% for patients in Group A and 21% for those in Group B. Only one recurrence was seen more than 2 years after treatment (Fig. 2) . Rates of distant recurrence were almost identical in both groups, at 18% at 1 year. No distant recurrence was observed 2 years after treatment (Fig. 3) .
Nine patients were diagnosed as having developed dementia secondary to radiation therapy, two in Group A and seven in Group B, but the difference in frequency was not statistically significant (p = 0.30, chi-square test). The radiation dose for these patients is shown in Table 3 . The neurological nominal stan dard dose (NSD) according to Sheline et a1.19) was also calculated. The neurological NSD was below 1000 neuret (660-880), which is considered to be the threshold for central nervous system damage, in all patients. 
Discussion
No prospective studies have shown the benefit of ad juvant WBRT. Several retrospective studies have claimed benefit from postoperative WBRT, but each study had a significant selection bias in terms of histology and the extent of disease .6,10) For example, DeAngelis et a1.6) reported better control of both local and distant recurrence in patients treated with surgery and adjuvant WBRT compared to surgery alone, but the histology of the primary lesions of the two groups differed significantly, including 9% of melanoma in the WBRT group compared to 37% in the non-WBRT group. Conclusions drawn from com parison of such non-homogeneous groups can be mis leading.
Our study of reasonably homogeneous groups of "good -risk" patients showed no apparent benefit of WBRT over local irradiation. The survival was ac tually worse in WBRT-treated group, but the reasons are not clear. We cannot exclude the effect of patient selection bias between the two treatment groups, which is an inherent problem of any retrospective study. However, the patient characteristics were simi lar, and we believe the effect of selection bias was small. One possible explanation is the tendency to better local control seen in patients receiving local ir radiation only, although this was not statistically sig nificant. The biological effect of single dose ir radiation is estimated to be two to three times greater than the same dose given in fractions.") Therefore, a patient treated by intraoperative radiation ther apy is considered to have received a larger dose than patients receiving WBRT.
Another important finding is that there was no difference in the frequency of distant recurrence be tween the two groups of patients, suggesting that the microscopic metastases grew to form clinically detectable new lesions in less than 20% of cases, and also that 30-50 Gy of WBRT was not sufficient to prevent the progression. Another possible expla nation is that all new metastases were the results of reseeding after the initial treatment. The frequency of new brain metastases in patients with non-small cell lung cancer is estimated as 28% in a large se ries. 12) Therefore, it is not impossible that new dis semination was the cause of brain recurrence, in which case WBRT would never be effective.
Brain atrophy and dementia caused by brain irradi ation is attracting more attention as the survival of patients improves with better cancer treat ments. 1,s,19,23> Asai et al. 1, 2) reported that post-irradia tion brain atrophy and dementia start to develop af ter 2-3 months, and reach a plateau in 6-10 months. Therefore, if the expected survival is longer than 6 months, the risk of radiation-induced dementia is sig nificant. They also showed that the frequency of de mentia positively correlates with the target volume of irradiation and the age of the patients. Unfortunate ly, cancer patients are relatively old and hence have a higher risk of dementia induced by WBRT. De Angelis et al.6) reported that dementia developed in 11 % of patients who survived more than a year after surgery and adjuvant WBRT, and suggested that the incidence could be higher. In our study, radiation-induced dementia was observed in 8.7% of patients receiving local irradiation, compared to 18.4% of those receiving WBRT. Although the dif ference was not significant, it is possible that a larger study could show statistical significance. The neuro logical NSD of any of these patients was below 1000 neuret, the dose usually considered to be the threshold for brain damage.") These data suggest that the WBRT of 30-40 Gy, which was not suf ficient to control the micrometastasis, was also not safe in terms of radiation-induced dementia. Single dose local irradiation therapies such as in traoperative radiation therapy and stereotactic radiosurgery have two major advantages. First, the treatment period can be shortened. Both intraopera tive radiation therapy and radiosurgery are 1-day procedures and the patient can be discharged shortly after the procedure. Second, the highly limited dose distribution enables re-irradiation in some cases, including patients who previously received WBRT. Several pilot studies of radiosurgery have shown promising results in the treatment of brain metasta ses.',') Although radiosurgery may not replace sur gery completely, its use is rapidly increasing be cause of the general effectiveness and minimal invasiveness. Intraoperative radiation therapy is also a viable option when a patient undergoes surgery, because it is performed as a single procedure in the operating room.
Our study relied mainly on CT for the detection of metastatic lesions. Although MR imaging with gadolinium enhancement is generally more sensitive than CT, we believe our results are still valid for two reasons. First, the number of cases in which MR im aging detects lesions which CT cannot visualize is rel atively small.4,22) Second, more sensitive detection would allow more strict selection of patients with soli tary metastases, which should strengthen rather than invalidate our conclusion.
In summary, our results showed no benefit from WBRT either in survival or in prevention of distant recurrence. Locally limited radiation therapy showed a tendency, although not statistically significant, to achieve better prevention of local recurrence and less radiation-induced dementia. Therefore, WBRT should not be used in patients with solitary brain metastasis from non-small cell lung cancer with resectable or resected primary lung lesion, and no other systemic dissemination. Treatment should be limited to the site of the single metastasis, which means surgical resection, if possible, followed by local radiation therapy. WBRT is usually a one-time treatment. If a patient previously treated with WBRT develops multiple brain metastases, more radiation is not usually warranted. Therefore, it should be withheld if the initial lesion is solitary. This approach will offer a better quality of life to patients for longer periods. Finally, some solitary brain metastases from other primary lesions do not seem to have aggressive behavior requiring WBRT. We believe locally limited treatment should be considered in these cases. A well-designed random ized study would address these issues. 
